Azitra Inc (AZTR)
XASE:AZTR
Top Page
Azitra Inc
(NYSE MKT:AZTR)
Select Model
Select Model
Rating:43Neutral
Price Target:
$0.23
▼(-24.67% Downside)
Action:ReiteratedDate:03/23/26
The score is primarily constrained by weak financial performance driven by persistent losses, heavy cash burn, and the severe 2025 deterioration. Corporate events are mixed—financing helps near-term funding, but delisting/noncompliance risk is a significant overhang—while technicals show only a partial short-term rebound and valuation is not supported due to negative earnings and no dividend.
Positive Factors
Proprietary microbial platform
Azitra’s AI-supported microbial engineering platform and focus on live biotherapeutics for dermatology create a durable technical moat. Targeting rare, treatment‑resistant skin diseases (ATR-12, ATR-04) supports high unmet need, potential regulatory incentives, and reusable platform economics across programs.
Negative Factors
Severe cash burn
Consistent, deep negative operating and free cash flow signals persistent funding dependence. The sharp 2025 deterioration markedly increases dilution and refinancing risk, forcing repeated capital raises that can constrain long-term strategy, slow development timelines, and dilute existing shareholders.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary microbial platform
Azitra’s AI-supported microbial engineering platform and focus on live biotherapeutics for dermatology create a durable technical moat. Targeting rare, treatment‑resistant skin diseases (ATR-12, ATR-04) supports high unmet need, potential regulatory incentives, and reusable platform economics across programs.
Read all positive factors
Azitra Inc (AZTR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.68M
Dividend YieldN/A
Average Volume (3M)169.78K
Price to Earnings (P/E)―
Beta (1Y)1.51
Revenue Growth-100.00%
EPS Growth93.82%
CountryUS
Employees12
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)1.15
Shares Outstanding16,192,438
10 Day Avg. Volume152,326
30 Day Avg. Volume169,784
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.27
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.96
Enterprise Value/Ebitda-0.10
Forecast
1Y Price Target
$1.00Price Target Upside233.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.85
Revenue Forecast (FY)N/A
Azitra Inc Business Overview & Revenue Model
Company Description
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified st...
How the Company Makes Money
Azitra is a clinical-stage company and, based on publicly available high-level company disclosures, it does not appear to generate material recurring revenue from commercial product sales. Its potential and/or historical sources of income typicall...
Azitra Inc Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
41
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 7.50M | 686.00K | 284.00K | 110.00K |
| Gross Profit | -453.14K | 7.50M | 686.00K | 284.00K | 110.00K |
| EBITDA | -10.49M | -8.50M | -10.67M | -10.02M | -8.79M |
| Net Income | -10.96M | -8.97M | -11.28M | -10.68M | -8.94M |
Balance Sheet | |||||
| Total Assets | 5.03B | 7.36M | 5.12M | 7.17M | 10.20M |
| Cash, Cash Equivalents and Short-Term Investments | 2.07B | 4.55M | 1.80M | 3.49M | 8.04M |
| Total Debt | 422.08M | 555.51K | 885.95K | 7.73M | 992.02K |
| Total Liabilities | 1.22B | 1.66M | 2.20M | 43.43M | 35.97M |
| Stockholders Equity | 3.80B | 5.70M | 2.91M | -36.26M | -25.77M |
Cash Flow | |||||
| Free Cash Flow | -11.25B | -10.56M | -7.68M | -8.69M | -8.72M |
| Operating Cash Flow | -11.22B | -10.18M | -7.36M | -8.35M | -8.07M |
| Investing Cash Flow | -182.91K | -379.25K | -318.26K | -336.76K | -652.27K |
| Financing Cash Flow | 8.92M | 13.32M | 5.98M | 4.13M | 992.86K |
Azitra Inc Technical Analysis
Negative
0.30
Price Trends
0.21
Positive
0.26
Negative
0.62
Negative
Market Momentum
<0.01
Positive
52.04
Neutral
37.76
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AZTR, the sentiment is Negative. The current price of 0.3 is above the 20-day moving average (MA) of 0.23, above the 50-day MA of 0.21, and below the 200-day MA of 0.62, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 52.04 is Neutral, neither overbought nor oversold. The STOCH value of 37.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AZTR.
Azitra Inc Risk Analysis
Azitra Inc disclosed 44 risk factors in its most recent earnings report. Azitra Inc reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Azitra Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | $3.68M | -0.12 | -215.04% | ― | -100.00% | 93.82% | |
| ― | $2.61M | -0.17 | -168.95% | ― | ― | 90.27% | |
42 Neutral | $2.37M | ― | -82.17% | ― | -3.27% | 51.83% | |
42 Neutral | $3.71M | -0.10 | -262.78% | ― | ― | 79.45% | |
| ― | $755.29K | -1.82 | -263.57% | ― | -34.58% | 96.41% |
* Healthcare Sector Average
AZTR
Azitra Inc
0.23
-1.71
-88.31%
OGEN
Oragenics
0.60
-5.13
-89.48%
INM
InMed Pharmaceuticals
0.72
-2.03
-73.91%
ENVB
Enveric Biosciences
1.96
-13.04
-86.91%
SPRC
SciSparc Ltd.
3.15
-50.46
-94.12%
ONCO
Onconetix
1.09
-25.39
-95.88%
Azitra Inc Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Azitra Secures PIPE Financing to Advance Cosmetic Programs
Positive
Mar 23, 2026
On March 18, 2026, Azitra Inc. entered into a private placement securities purchase agreement with institutional and insider investors to sell Series A convertible preferred stock and accompanying Series B and C warrants. The PIPE financing, which...
Delistings and Listing ChangesFinancial DisclosuresRegulatory Filings and Compliance
Azitra Faces NYSE American Noncompliance and Delisting Risk
Negative
Mar 13, 2026
Azitra Inc., a clinical-stage biopharmaceutical company specializing in precision dermatology, is developing live biotherapeutic products including ATR-12 for Netherton syndrome and ATR-04 for EGFR inhibitor–associated rash, supported by an ...
Business Operations and StrategyShareholder Meetings
Azitra Cancels Special Stockholder Meeting and Proposals
Negative
Mar 5, 2026
Azitra Inc., a clinical-stage biopharmaceutical company specializing in precision dermatology therapies for severe skin conditions such as Netherton syndrome and EGFR inhibitor–associated rash, develops live biotherapeutic candidates ATR-12 ...
Private Placements and FinancingShareholder Meetings
Azitra Reschedules Special Meeting to Approve Share Issuance
Neutral
Feb 6, 2026
On February 6, 2026, Azitra Inc. convened but immediately adjourned a special meeting of stockholders after determining that only about 13% of outstanding common shares were represented, well below the one‑third quorum requirement, and resch...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.